Eisai and Merck enter collaboration to explore novel combination regimens of Anti-PD-1
Eisai and Merck announce a clinical trial collaboration to evaluate safety, tolerability and efficacy of Merck’s anti-PD-1 therapy, pembrolizumab, in combination with Eisai oncology compounds lenvatinib mesylate and eribulin mesylate in multiple clinical trials. March 04, 2015